Publications by authors named "Richard Skells"
Background: Window-of-opportunity trials, evaluating the engagement of drugs with their biological target in the time period between diagnosis and standard-of-care treatment, can help prioritise promising new systemic treatments for later-phase clinical trials. Renal cell carcinoma (RCC), the 7 commonest solid cancer in the UK, exhibits targets for multiple new systemic anti-cancer agents including DNA damage response inhibitors, agents targeting vascular pathways and immune checkpoint inhibitors. Here we present the trial protocol for the WIndow-of-opportunity clinical trial platform for evaluation of novel treatment strategies in REnal cell cancer (WIRE).
View Article and Find Full Text PDFArticle Synopsis
- - Rapid COVID-19 diagnosis is crucial in hospitals, but traditional nose/throat swabs often yield negative results for 30%-50% of patients using nucleic acid amplification testing (NAAT) for SARS-CoV-2.
- - The D614G spike mutant is prevalent, raising questions on how well existing antibody tests detect this variant compared to the original strain.
- - Combining rapid antibody point-of-care tests with NAAT significantly improves detection rates for COVID-19, achieving a sensitivity of 79.2% and maintaining high specificity regardless of the D614G variant.